Evidence map›Paper›PMID 39144544›Full record

ArticleNIHR open research2023

NIHR Global Health Research Group on Vaccines for vulnerable people in Africa (VAnguard): Concept and Launch event report.

Ludoviko Zirimenya, Flavia Zalwango, Esther A Owino, Henry K Karanja, Agnes Natukunda, Gyaviira Nkurunungi, Victoria Bukirwa, Achilles Kiwanuka, Monica Chibita, Reagan Mogire and 5 more

Abstract read
In one paragraph

Article in NIHR open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ludoviko ZirimenyaLondon School of Hygiene & Tropical Medicine, London, UK.
Flavia ZalwangoUganda Virus Research Institute, Entebbe, 49, Uganda.
Esther A OwinoClinical Research, KEMRI Wellcome Trust Research Programme, Kilifi, 230, Kenya.ORCID https://orcid.org/0000-0002-5424-6327
Henry K KaranjaUganda Virus Research Institute, Entebbe, 49, Uganda.ORCID https://orcid.org/0000-0002-8249-6833
Agnes NatukundaLondon School of Hygiene & Tropical Medicine, London, UK.
Gyaviira NkurunungiLondon School of Hygiene & Tropical Medicine, London, UK.ORCID https://orcid.org/0000-0003-4062-9105
Victoria BukirwaUganda Virus Research Institute, Entebbe, 49, Uganda.
Achilles KiwanukaLondon School of Hygiene & Tropical Medicine, London, UK.
Monica ChibitaJournalism, Media & Communication, Uganda Christian University, Mukono, 4, Uganda.ORCID https://orcid.org/0000-0002-8398-138X
Reagan MogireClinical Research, KEMRI Wellcome Trust Research Programme, Kilifi, 230, Kenya.ORCID https://orcid.org/0000-0001-6454-1613
Primus ChiClinical Research, KEMRI Wellcome Trust Research Programme, Kilifi, 230, Kenya.ORCID https://orcid.org/0000-0002-2727-2693
Emily WebbLondon School of Hygiene & Tropical Medicine, London, UK.
Pontiano KaleebuLondon School of Hygiene & Tropical Medicine, London, UK.
Alison M ElliottLondon School of Hygiene & Tropical Medicine, London, UK.ORCID https://orcid.org/0000-0003-2818-9549
NIHR VAnguard group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Vaccination is an important public health intervention, but not everyone benefits equally. Biological, social and structural factors render some communities vulnerable and unable to secure optimal health benefits from vaccination programmes. This drives health inequity and undermines wider vaccine impact by allowing the persistence of non-immune communities as foci for recurrent disease outbreaks. The NIHR Global Health Research Group on Vaccines for vulnerable people in Africa (VAnguard) aims to understand how biological, social, and structural factors interact to impair vaccine impact in vulnerable African communities. Methods: The VAnguard project will be implemented through three thematic work packages (1-3) and four cross-cutting work packages (4-7). Work package 1 will investigate the biological drivers and mechanisms of population differences in vaccine responses. Work package 2 will support the understanding of how structural, social and biological determinants of vaccine response interrelate to determine vaccine impact. Work package 3 will synthesise data and lead analyses to develop, model and test community-based integrated strategies to optimise vaccine access, uptake and effectiveness. Work package 4 will plan and implement field investigations (community survey and qualitative studies (with support of work package 2) to explore structural, social & biological determinants impairing vaccine impact. Work package 5 will collaborate with work packages 1-4, to engage communities in designing interventions that aim to directly optimise vaccine impact through a process of co-learning and co-creation between them and the researchers. Work package 6 will build capacity for, and a culture of, consultative, collaborative multidisciplinary vaccine research in East Africa. Work package 7 will support the overall project management and governance. Following the project inception on the 1 Conclusion: Results from this project will contribute to the development of integrated strategies that will optimise vaccine benefits and drive health equity.

Indexed as

Community engagementHealth equityKenyaUgandaVaccine effectivenessVaccine impactVaccinesVulnerable communities

Identifiers

PMID39144544
PMCPMC11323737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.